Methods of reducing mammographic breast density and/or breast cancer risk
The present disclosure is directed to generally methods for treating mammographic breast density and/or breast stiffness in a patient in need thereof, such as a premenopausal or perimenopausal patient, comprising the administration of an effective amount of androgenic agent and an effective amount of an aromatase inhibitor. These methods may also be useful in post-menopausal woman.
1. A method of treating mammographic breast density and/or breast stiffness in a patient in need thereof, comprising administering to the patient:
i) an effective amount of an androgenic agent selected from the group consisting of: testosterone, methyltestosterone, enanthate testosterone, propionate testosterone, cypionate testosterone, and undecanoate testosterone; and
ii) 0.1-10 mg of anastrozole;
wherein the method mitigates or reduces the treated patient's risk of developing breast cancer.
2. The method of claim 1 , wherein the patient is peri-menopausal.
3. The method of claim 1 , wherein the patient is premenopausal.
4. The method of claim 1 , wherein the patient's breast has a mammographic breast density of 25% or greater via 2-D determination.
5. The method of claim 1 , wherein the patient's breast has a BIRADS score of 3 or 4 (or c or d).
6. The method of claim 1 , wherein the patient's breast has a mammographic breast density of 7.5% or greater via 3-D determination.
7. The method of claim 1 , wherein the method reduces or decreases the mammographic breast density of the patient's breast between one or more annual intervening mammographic detections.
8. The method of claim 1 , wherein the method reduces or decreases the breast stiffness of the patient's breast between one or more annual intervening mammographic detections.
9. The method of claim 1 , wherein the method reduces or decreases the patient's pain during breast compression.
10. The method of claim 1 , wherein the method reduces or minimizes the patient's BIRADS score by 1 or more points between one or more annual intervening mammographic detections.
11. The method of claim 1 , wherein the method enhances, increases, or improves, one or more of the following:
i) mammographic visualization or detection of the patient's breast;
ii) breast compression during mammographic visualization or detection of the patient's breast;
iii) the treated patient's compliance of having regular mammographic visualizations or detections; or
iv) combinations thereof.
12. The method of claim 1 , wherein the anastrozole is administered to the patient orally, transdermally or via a subcutaneous implant.
13. The method of claim 1 , wherein the anastrozole is administered in an amount of 1 mg, 2 mg, 3 mg, 4 mg, 5 mg, or 6 mg.
14. The method of claim 1 , wherein the androgenic agent is administered to the patient via a subcutaneous implant, injection, transdermally, or by intramuscular administration.
15. The method of claim 14 , wherein the androgenic agent is testosterone.
16. The method of claim 15 , wherein the effective amount of the testosterone is in the range of between 30-150 mg.
17. The method of claim 1 , wherein the androgenic agent is enanthate testosterone, propionate testosterone, cypionate testosterone, or undecanoate testosterone.
18. The method of claim 1 , wherein the androgenic agent is methyltestosterone.
19. The method of claim 1 , wherein the patient is post-menopausal.